- Home
- ZBAI vs ATYR Comparison
ZBAI vs ATYR Comparison
Compare ZBAI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 6 | 58 |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 73.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBAI | ATYR |
|---|---|---|
| Price | $6.36 | $0.73 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 5.9K | ★ 998.5K |
| Earning Date | 03-13-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.64 |
| 52 Week High | $11.94 | $7.29 |
Technical Indicators
Market Signals| Indicator | ZBAI | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 36.57 |
| Support Level | $5.40 | $0.67 |
| Resistance Level | $6.39 | $0.85 |
| Average True Range (ATR) | 0.55 | 0.05 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 89.16 | 11.12 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).